Dopavision Appoints Dirk Sauer, PhD, as Chair of the Company's Advisory Board

Dopavision announced the appointment of Dirk Sauer, PhD, as Chairman of the company's Advisory Board. Dr. Sauer brings an exceptional track record in the development of ophthalmic therapeutics and an extensive industry network to advance MyopiaX, Dopavision's digital therapeutic for childhood myopia control. MyopiaX is currently in clinical trials in Germany, Portugal, Spain, and Ireland.

Dr. Sauer is an expert in eye therapeutics development with long-standing global experience in ophthalmology and neuroscience. At Novartis Pharma, he led numerous projects and teams during all phases of the drug development process and was, among others, responsible for the development of ophthalmology therapies to treat the wet form of macular degeneration. Furthermore, he led the company’s Ophthalmology Development Unit as Global Development Unit Head for more than 9 years. During that time, he built a development portfolio in various ocular indications, spanning from small molecules to biologics, gene therapies, and digital therapeutics. His leadership included the development unit of the former Alcon Pharma franchise.

"Dirk brings extremely valuable knowledge in both research and product development," said Mark Wuttke, CEO of Dopavision. "He is familiar with a wealth of indications affecting both back and front of the eye, the selection of the best approaches and the challenges of bringing them to market. He will be a great addition to our Advisory Board and will provide leadership for the entire R&D team."